Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

N Engl J Med. 2022 Sep 29;387(13):1185-1195. doi: 10.1056/NEJMoa2203094. Epub 2022 Aug 27.

Abstract

Background: Whether acetazolamide, a carbonic anhydrase inhibitor that reduces proximal tubular sodium reabsorption, can improve the efficiency of loop diuretics, potentially leading to more and faster decongestion in patients with acute decompensated heart failure with volume overload, is unclear.

Methods: In this multicenter, parallel-group, double-blind, randomized, placebo-controlled trial, we assigned patients with acute decompensated heart failure, clinical signs of volume overload (i.e., edema, pleural effusion, or ascites), and an N-terminal pro-B-type natriuretic peptide level of more than 1000 pg per milliliter or a B-type natriuretic peptide level of more than 250 pg per milliliter to receive either intravenous acetazolamide (500 mg once daily) or placebo added to standardized intravenous loop diuretics (at a dose equivalent to twice the oral maintenance dose). Randomization was stratified according to the left ventricular ejection fraction (≤40% or >40%). The primary end point was successful decongestion, defined as the absence of signs of volume overload, within 3 days after randomization and without an indication for escalation of decongestive therapy. Secondary end points included a composite of death from any cause or rehospitalization for heart failure during 3 months of follow-up. Safety was also assessed.

Results: A total of 519 patients underwent randomization. Successful decongestion occurred in 108 of 256 patients (42.2%) in the acetazolamide group and in 79 of 259 (30.5%) in the placebo group (risk ratio, 1.46; 95% confidence interval [CI], 1.17 to 1.82; P<0.001). Death from any cause or rehospitalization for heart failure occurred in 76 of 256 patients (29.7%) in the acetazolamide group and in 72 of 259 patients (27.8%) in the placebo group (hazard ratio, 1.07; 95% CI, 0.78 to 1.48). Acetazolamide treatment was associated with higher cumulative urine output and natriuresis, findings consistent with better diuretic efficiency. The incidence of worsening kidney function, hypokalemia, hypotension, and adverse events was similar in the two groups.

Conclusions: The addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure resulted in a greater incidence of successful decongestion. (Funded by the Belgian Health Care Knowledge Center; ADVOR ClinicalTrials.gov number, NCT03505788.).

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide* / adverse effects
  • Acetazolamide* / therapeutic use
  • Acute Disease
  • Carbonic Anhydrase Inhibitors* / adverse effects
  • Diuretics* / adverse effects
  • Diuretics* / therapeutic use
  • Double-Blind Method
  • Heart Failure* / drug therapy
  • Humans
  • Natriuretic Peptide, Brain / analysis
  • Sodium
  • Sodium Potassium Chloride Symporter Inhibitors / therapeutic use
  • Stroke Volume
  • Symptom Flare Up
  • Treatment Outcome
  • Ventricular Function, Left
  • Water-Electrolyte Imbalance* / drug therapy
  • Water-Electrolyte Imbalance* / etiology
  • Water-Electrolyte Imbalance* / therapy

Substances

  • Carbonic Anhydrase Inhibitors
  • Diuretics
  • Sodium Potassium Chloride Symporter Inhibitors
  • Natriuretic Peptide, Brain
  • Sodium
  • Acetazolamide

Associated data

  • ClinicalTrials.gov/NCT03505788